within Pharmacolibrary.Drugs.ATC.P;

model P01CX02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.4999999999999995e-06,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.011300000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0295,
    k12             = 0.69,
    k21             = 0.69
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P01CX02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Suramin sodium is a polysulfonated naphthylurea originally developed as an antiparasitic agent for the treatment of African sleeping sickness (trypanosomiasis) and river blindness (onchocerciasis). It acts primarily by inhibiting enzymes involved in energy metabolism in protozoa and helminths. It is not widely used today except in specific settings due to the development of resistance and the advent of safer pharmaceuticals.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model parameters reported for adult male subjects receiving intravenous suramin sodium for therapeutic purposes.</p><h4>References</h4><ol><li><p>Collins, JM, et al., &amp; Myers, CE (1986). Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. <i>Journal of clinical pharmacology</i> 26(1) 22–26. DOI:<a href=\"https://doi.org/10.1002/j.1552-4604.1986.tb02897.x\">10.1002/j.1552-4604.1986.tb02897.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3005375/\">https://pubmed.ncbi.nlm.nih.gov/3005375</a></p></li><li><p>Ogden, A, et al., &amp; Au, JL (2004). Suramin as a chemosensitizer: oral pharmacokinetics in rats. <i>Pharmaceutical research</i> 21(11) 2058–2063. DOI:<a href=\"https://doi.org/10.1023/b:pham.0000048197.77546.75\">10.1023/b:pham.0000048197.77546.75</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15587928/\">https://pubmed.ncbi.nlm.nih.gov/15587928</a></p></li><li><p>Hutson, PR, et al., &amp; Wilding, G (1993). Evidence of an absorption phase after short intravenous suramin infusions. <i>Cancer chemotherapy and pharmacology</i> 31(6) 495–499. DOI:<a href=\"https://doi.org/10.1007/BF00685042\">10.1007/BF00685042</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8453691/\">https://pubmed.ncbi.nlm.nih.gov/8453691</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P01CX02;
